Zhihua Li
Zhihua Li
Verifierad e-postadress på fda.hhs.gov
Citeras av
Citeras av
Extensive terminal and asymmetric processing of small RNAs from rRNAs, snoRNAs, snRNAs, and tRNAs
Z Li, C Ender, G Meister, PS Moore, Y Chang, B John
Nucleic acids research 40 (14), 6787-6799, 2012
A sensitive non-radioactive northern blot method to detect small RNAs
SW Kim, Z Li, PS Moore, AP Monaghan, Y Chang, M Nichols, B John
Nucleic acids research 38 (7), e98-e98, 2010
A new perspective in the field of cardiac safety testing through the comprehensive in vitro proarrhythmia assay paradigm
B Fermini, JC Hancox, N Abi-Gerges, M Bridgland-Taylor, KW Chaudhary, ...
Journal of biomolecular screening 21 (1), 1-11, 2016
An in-depth map of polyadenylation sites in cancer
Y Lin, Z Li, F Ozsolak, SW Kim, G Arango-Argoty, TT Liu, SA Tenenbaum, ...
Nucleic acids research 40 (17), 8460-8471, 2012
Improving the in silico assessment of proarrhythmia risk by combining hERG (human ether-ā-go-go-related gene) channel–drug binding kinetics and multichannel pharmacology
Z Li, S Dutta, J Sheng, PN Tran, W Wu, K Chang, T Mdluli, DG Strauss, ...
Circulation: Arrhythmia and Electrophysiology 10 (2), e004628, 2017
Optimization of an In silico Cardiac Cell Model for Proarrhythmia Risk Assessment
S Dutta, KC Chang, KA Beattie, J Sheng, PN Tran, WW Wu, M Wu, ...
Frontiers in Physiology 8, 616, 2017
Regulatory circuit of human microRNA biogenesis
J Lee, Z Li, R Brower-Sinning, B John
PLoS computational biology 3 (4), e67, 2007
Mechanistic model‐informed proarrhythmic risk assessment of drugs: review of the “CiPA” initiative and design of a prospective clinical validation study
J Vicente, R Zusterzeel, L Johannesen, J Mason, P Sager, V Patel, ...
Clinical Pharmacology & Therapeutics 103 (1), 54-66, 2018
Assessment of an In Silico Mechanistic Model for Proarrhythmia Risk Prediction Under the CiPA Initiative
Z Li, BJ Ridder, X Han, WW Wu, J Sheng, PN Tran, M Wu, A Randolph, ...
Clinical Pharmacology & Therapeutics 105 (2), 466-475, 2019
Comprehensive in vitro proarrhythmia assay (CiPA) update from a cardiac safety research consortium/health and environmental sciences institute/FDA meeting
DG Strauss, G Gintant, Z Li, W Wu, K Blinova, J Vicente, JR Turner, ...
Therapeutic Innovation & Regulatory Science 53 (4), 519-525, 2019
Uncertainty quantification reveals the importance of data variability and experimental design considerations for in silico proarrhythmia risk assessment
KC Chang, S Dutta, GR Mirams, KA Beattie, J Sheng, PN Tran, M Wu, ...
Frontiers in physiology, 917, 2017
Characterization of viral and human RNAs smaller than canonical MicroRNAs
Z Li, SW Kim, Y Lin, PS Moore, Y Chang, B John
Journal of virology 83 (24), 12751-12758, 2009
General Principles for the Validation of Proarrhythmia Risk Prediction Models: An Extension of the CiPA In Silico Strategy
Z Li, GR Mirams, T Yoshinaga, BJ Ridder, X Han, JE Chen, ...
Clinical Pharmacology & Therapeutics 107 (1), 102-111, 2020
Identification, expression and functional characterization of the GRAL gene
Z Li, B Wang, X Wu, SY Cheng, L Paraoan, J Zhou
Journal of neurochemistry 95 (2), 361-376, 2005
A temperature-dependent in silico model of the human ether-ā-go-go-related (hERG) gene channel
Z Li, S Dutta, J Sheng, PN Tran, W Wu, T Colatsky
Journal of pharmacological and toxicological methods 81, 233-239, 2016
The effect of antibiotics on the gut microbiome: a metagenomics analysis of microbial shift and gut antibiotic resistance in antibiotic treated mice
L Xu, A Surathu, I Raplee, A Chockalingam, S Stewart, L Walker, L Sacks, ...
BMC genomics 21 (1), 1-18, 2020
A systematic strategy for estimating hERG block potency and its implications in a new cardiac safety paradigm
BJ Ridder, DJ Leishman, M Bridgland-Taylor, M Samieegohar, X Han, ...
Toxicology and applied pharmacology 394, 114961, 2020
Noncoding RNAs that associate with YB-1 alter proliferation in prostate cancer cells
TT Liu, G Arango-Argoty, Z Li, Y Lin, SW Kim, A Dueck, F Ozsolak, ...
Rna 21 (6), 1159-1172, 2015
Translational models and tools to reduce clinical trials and improve regulatory decision making for QTc and proarrhythmia risk (ICH E14/S7B updates)
DG Strauss, WW Wu, Z Li, J Koerner, C Garnett
Clinical Pharmacology & Therapeutics 109 (2), 319-333, 2021
Characterization of loperamide-mediated block of hERG channels at physiological temperature and its proarrhythmia propensity
J Sheng, PN Tran, Z Li, S Dutta, K Chang, T Colatsky, WW Wu
Journal of Pharmacological and Toxicological Methods 88, 109-122, 2017
Systemet kan inte utföra åtgärden just nu. Försök igen senare.
Artiklar 1–20